Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Follow-Up Questions
Affymax Inc (AFFY) 的本益比是多少？
Affymax Inc 的本益比是 N/A
Affymax Inc 的 CEO 是誰？
Mr. Jonathan Couchman 是 Affymax Inc 的 President，自 2014 加入公司。
